Anti-Parkinson Drug Biperiden Inhibits Enzyme Acetylcholinesterase

Biomed Res Int. 2017:2017:2532764. doi: 10.1155/2017/2532764. Epub 2017 Jul 13.

Abstract

Biperiden is a drug used in Parkinson disease treatment and it serves also as an antiseizures compound in organophosphates poisoning. It acts as antagonist of muscarinic receptor activated by acetylcholine while the enzyme acetylcholinesterase (AChE) cleaves acetylcholine in synaptic junction into choline and acetic acid. This enzyme is inhibited by various compounds; however there has not been proposed evidence about interaction with biperiden molecule. We investigated this interaction using standard Ellman's assay and experimental findings were critically completed with an in silico prediction by SwissDock docking software. Uncompetitive mechanism of action was revealed from Dixon plot and inhibition constant (Ki ) was calculated to be 1.11 mmol/l. The lowest predicted binding energy was -7.84 kcal/mol corresponding to H-bond between biperiden molecule and Tyr 341 residuum in protein structure of AChE. This interaction seems to be further stabilized by π-π interaction with Tyr 72, Trp 286, and Tyr 341. In conclusion, biperiden appears as a very weak inhibitor but it can serve as a lead structure in a pharmacological research.

MeSH terms

  • Acetylcholinesterase / metabolism*
  • Biperiden / chemistry
  • Biperiden / pharmacology
  • Biperiden / therapeutic use*
  • Cholinesterase Inhibitors / chemistry
  • Cholinesterase Inhibitors / pharmacology
  • Cholinesterase Inhibitors / therapeutic use*
  • Enzyme Assays
  • Humans
  • Models, Molecular
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / enzymology*
  • Substrate Specificity / drug effects

Substances

  • Cholinesterase Inhibitors
  • Biperiden
  • Acetylcholinesterase